Advertisement

Topics

Ocera doses first patient in Phase IIa trial of OCR-002 to treat cirrhosis

19:00 EDT 4 Jun 2017 | Net Resources International

Ocera Therapeutics has started dosing patients in the Phase IIa part of its Phase I/IIa clinical trial of oral OCR-002 (ornithine phenylacetate) for the treatment of cirrhosis.

Original Article: Ocera doses first patient in Phase IIa trial of OCR-002 to treat cirrhosis

NEXT ARTICLE

More From BioPortfolio on "Ocera doses first patient in Phase IIa trial of OCR-002 to treat cirrhosis"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...